



News Release

Suven's revenue up by 24% and spends 17% of revenue on R&D

HYDERABAD, INDIA (August 13, 2011) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its un-audited financial results for the quarter ended 30th June 2011. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 13th Aug 2011 at Hyderabad.

Financial Highlights for the 1st Quarter ended June' 2011:

Growth in revenue Rs 448.4 mil vs. Rs 363.1 mil ... 23.48%
Growth in PAT Rs 33.6 mil vs. Rs 34.4 mil ... (2.46%)
Growth in EBIDTA Rs 53.7 mil vs. Rs 45.5 mil ... 17.96%

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 74.8 mil (16.68% on revenue) for the quarter ended June' 2011.

During the quarter there were major qualitative achievements with the grant of 13 product patents to Suven's drug discovery pipeline which consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development targeting conditions such as ADHD, Dementia, Depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

Also during the quarter, Suven's Alzheimer drug candidate SUVN-502 successfully completed all chronic toxicological (tox) studies and demonstrated very high margin of safety (MOS) , bags "Bio-Excellence Award at Bangalore India Bio 2011" and UNIT-III RECEIVES US FDA ACCEPTANCE.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.